Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

New study tracks psoriasis drug in Real-World greek patients

NCT ID NCT06247319

Disease control Sponsor: AbbVie Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing This study
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study follows 250 adults in Greece who were recently diagnosed with moderate plaque psoriasis and are starting risankizumab, a drug that calms the overactive immune system. Researchers will measure how much the skin clears up and how quality of life improves over two years. Participants receive the drug as part of their normal care, with no extra tests or visits required.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Participants

250 people

The number who actually took part.

Started

Apr 2024

Expected to finish

Oct 2027

An estimate. End dates often move.

Lead sponsor

A company

The lead sponsor is a pharmaceutical, biotech, or medical-device company.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Who is studied

Participants with a recent diagnosis of moderate plaque PsO (defined as ≤24 months since the first diagnosis of moderate PsO), and naïve to advanced treatments (biologics, apremilast, and deucravacitinib) treated with Risakizumab according to local label.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Participants with a confirmed diagnosis of moderate plaque PsO made by a specialist ≤24 months prior to risankizumab prescription defined as: * Percentage of body surface affected by PsO Body Surface Area (BSA) \>2% and \<20% * Psoriasis Area and Severity Index (PASI) score \>10 * Static Physician's Global Assessment (sPGA) score =3 (moderate) based on a 5-point scale (0-4) * Participants naïve to advanced treatments (biologics, apremilast, and deucravacitinib) * Participants who have been prescribed treatment with risankizumab in line with marketing authorization and local access conditions, prior to signed Informed Consent * Decision to treat with risankizumab has been made independently and prior to enrolment in the study * Participants must be willing and able to read and complete the study specific questionnaires Exclusion Criteria: * Participants who currently receive treatment with any investigational drug/device/intervention or who have received any investigational product within 30 days before risankizumab initiation * Pregnancy or lactation * Unwilling or unable to provide informed consent

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Moderate plaque psoriasis are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

psoriasis

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Moderate plaque psoriasis Moderate psoriasis Psoriasis

Contacts and locations

Locations

  • 251 Hellenic Air Force General Hospital /ID# 268135

    Athens, Attica, 11527, Greece

  • 401 General Military Hospital /ID# 277393

    Athens, 11525, Greece

  • Asklipieio General Hospital of Voula /ID# 268136

    Voula, Attica, 16673, Greece

  • General Hospital Andreas Syggros /ID# 263443

    Athens, Attica, 16121, Greece

  • General Hospital Andreas Syggros /ID# 266248

    Athens, Attica, 16121, Greece

  • General Hospital of Thessaloniki "Agios Pavlos'' /ID# 267506

    Thessaloniki, 55134, Greece

  • General Hospital of Tripoli Panarkadiko "Evangelistria" /ID# 266251

    Tripoli, 22100, Greece

  • General Hospital of Xanthi /ID# 268133

    Xánthi, 67100, Greece

  • Hospital of Skin and Venereal Diseases- Thessaloniki /ID# 262530

    Thessaloniki, 54643, Greece

  • Hospital of Skin and Venereal Diseases- Thessaloniki /ID# 263452

    Thessaloniki, 54643, Greece

  • Hygeia Hospital /ID# 263455

    Athens, 15123, Greece

  • Iatriko Psichikou /ID# 272851

    Athens, Attica, 11525, Greece

  • KAT Attica General Hospital /ID# 266249

    Kifissia, 14561, Greece

  • Konstantopoulio General Hospital /ID# 266257

    Nea Ionia, Magnisia, 14233, Greece

  • Olympion General Clinic /ID# 266258

    Pátrai, Achaia, 25443, Greece

  • Papageorgiou General Hospital /ID# 262529

    Thessaloniki, 56429, Greece

  • Tzaneio Prefecture General Hospital of Piraeus /ID# 263448

    Piraeus, Attica, 18536, Greece

  • University General Hospital Attikon /ID# 263442

    Athens, Attica, 12462, Greece

  • University General Hospital of Heraklion /ID# 268777

    Heraklion, Crete, 71500, Greece

  • University General Hospital of Larissa /ID# 263440

    Larissa, 41110, Greece

  • Venizelio Regional General Hospital of Heraklion /ID# 268778

    Heraklion, Irakleio, 71409, Greece

  • West Attica General Hospital "Agia Varvara" /ID# 266256

    Agía Varvára, 12351, Greece

More trials for these conditions

Other studies related to the condition(s) this trial covers.